 | • レポートコード：MRC2303G108 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥665,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,225,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の抗凝固剤拮抗薬市場規模が、予測期間中、CAGR 12.01％で増加すると推測されています。本書では、抗凝固剤拮抗薬の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（濃縮プロトロンビン複合体、凝固因子、モノクローナル抗体、ビタミンK1、その他）分析、エンドユーザー別（病院薬局、小売薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Portola Pharmaceuticals Inc.、Boehringer Ingelheim GmbH、CSL Behring Limited、Pfizer Inc.、Octapharma AG、Bausch Health Companies Inc.などが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗凝固剤拮抗薬市場規模：薬剤クラス別 - 濃縮プロトロンビン複合体の市場規模 - 凝固因子の市場規模 - モノクローナル抗体の市場規模 - ビタミンK1の市場規模 - その他抗凝固剤拮抗薬の市場規模 ・世界の抗凝固剤拮抗薬市場規模：エンドユーザー別 - 病院薬局における市場規模 - 小売薬局における市場規模 - その他エンドユーザーにおける市場規模 ・世界の抗凝固剤拮抗薬市場規模：地域別 - 北米の抗凝固剤拮抗薬市場規模 アメリカの抗凝固剤拮抗薬市場規模 カナダの抗凝固剤拮抗薬市場規模 メキシコの抗凝固剤拮抗薬市場規模 … - ヨーロッパの抗凝固剤拮抗薬市場規模 ドイツの抗凝固剤拮抗薬市場規模 イギリスの抗凝固剤拮抗薬市場規模 フランスの抗凝固剤拮抗薬市場規模 … - アジア太平洋の抗凝固剤拮抗薬市場規模 中国の抗凝固剤拮抗薬市場規模 日本の抗凝固剤拮抗薬市場規模 インドの抗凝固剤拮抗薬市場規模 … - 南米/中東の抗凝固剤拮抗薬市場規模 ブラジルの抗凝固剤拮抗薬市場規模 アルゼンチンの抗凝固剤拮抗薬市場規模 サウジアラビアの抗凝固剤拮抗薬市場規模 ・競争状況 ・市場機会・将来動向 |
The anticoagulant reversal drugs market is expected to witness a CAGR of 12.01% over the forecast period.
COVID-19 significantly impacted the anticoagulant reversal drugs market owing to the increasing pace of research activities on COVID-19 infection. For instance, per the data from the American Journal of Cardiovascular Drugs, in 2020, more than 10 clinical trials were in progress to evaluate the potential of factor Xa inhibitors in COVID-19 patients, and research on strategies for the parenteral administration of these drugs was worked upon to be used in critically ill COVID-19 patients. Additionally, it was observed that several patients with COVID-19 had developed abnormal blood clotting, which increased the use of anticoagulants during the pandemic. Therefore, the COVID-19 pandemic had a significant impact on the market studied. However, the market is currently reaching its pre-pandemic nature and is expected to witness healthy growth in the coming years.
The major factors driving the market are a rise in the global prevalence of multiple cardiovascular indications, atrial fibrillation, an increase in intracranial and gastrointestinal hemorrhages, and the increasing geriatric population. As per the 2021 data from the CDC, every year, 805,000 people in the United States have a heart attack, 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. Similarly, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease. The increasing burden of cardiovascular diseases in major countries such as the United States is believed to propel market growth over the forecast period.
Additionally, the increasing burden of blood diseases is augmenting the demand for anticoagulant reversal drugs. For instance, as per the National Family Health Surveys (NFHS) conducted in 2021, the prevalence of anemia in Indian adults was around 59% in women and 31% in men in 2021. With this development, there will be market growth in the coming years.
However, the side effects associated with the drug may restrain the market during the forecast period.
Anticoagulant Reversal Drugs Market Trends
The Coagulation Factors Segment is Expected to Hold the Largest Market Share
Coagulation factors, also called clotting factors, are the proteins in the blood. They help form a blood clot to stop bleeding when an injury occurs.
It has been observed that COVID-19 caused blood clotting in most patients, propelling the demand for anticoagulants during the pandemic. According to a research article published in the Lancet in 2020, coagulopathy of varying severity was observed in most COVID-19-infected patients, characterized by increased D-dimer levels and fibrinogen or fibrin degradation products, along with abnormal measurements in the prothrombin time, acute partial thromboplastin time, and platelet counts. Hence, thorough research on various factors affecting bleeding and coagulation among COVID-19 patients was carried out to understand the pathophysiology of the causal organism.
Besides, Andexxa is the first and only approved drug for reversing the effect of coagulation factor Xa inhibitors in adult patients. Portola Pharmaceuticals introduced Andexxa in the year 2018, which contributed to a major share of the company’s revenue. Currently, Andexxa is sold by AstraZeneca because it acquired Alexion Pharmaceuticals, the parent company of Portola Pharmaceuticals in July 2021.
Additionally, the increasing research activities in the development of new products by companies are expected to drive the growth of the studied segment over the forecast period. For instance, the American College of Cardiology stated in its June 2022 study that for atrial fibrillation, there will be a growing new drug development wave that will fulfill the need for anticoagulants in the coming years. With the focus of companies on developing anticoagulants, the segment is believed to witness strong growth over the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America is expected to dominate the overall anticoagulant reversal drugs market throughout the forecast period. The high growth of the studied market in North America is due to factors such as the availability of direct reimbursement policies and the region’s advanced healthcare infrastructure.
COVID-19 significantly impacted the market studied in the North American region due to the emergence of the relationship between COVID-19 infection and blood disorders. For instance, as per 2020 data from the American Journal of Hematology, COVID-19-infected patients admitted with severe complications associated with the viral infection were found to exhibit high levels of blood-clotting protein Factor V, which could eventually lead to the development of blood clots in various organs.
Moreover, the United States holds the largest market share due to the accelerated drug approval initiative by the US FDA and the initiation of various prevention programs and awareness workshops for blood disorders by the CDC, which is expected to drive market growth in this region. Also, the high prevalence of cardiovascular diseases in the United States drives the studied market. According to the American Heart Association 2021 data, myocardial infarction is more common in the United States and it has been observed that every 40 seconds at least one person have a myocardial infarction. Additionally, coronary events occur in about 1,055,000 individuals annually, including 720,000 new and 335,000 recurrent coronary events.
Additionally, several key players in the studied market have a base in the United States and are expected to explore the market through R&D activities and product approvals. Thus, given the aforementioned factors, the anticoagulant reversal drugs market is anticipated to grow significantly over the forecast period in North America.
Anticoagulant Reversal Drugs Market Competitor Analysis
The anticoagulant reversal drugs market is consolidated and consists of a few major players. The key players in the studied market include Pfizer Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Portola Pharmaceuticals Inc., and Octapharma AG, among others. Some prominent players are vigorously making acquisitions with other companies to consolidate their market positions across the globe, while others are launching generic products and increasing investments in research and development activities.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population and Growing Blood Disorders
4.2.2 New Product Launches due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Side Effects Associated with the Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size – Value in USD million)
5.1 By Drug Class
5.1.1 Prothrombin Complex Concentrates
5.1.2 Coagulation Factors
5.1.3 Monoclonal Antibodies
5.1.4 Phytonadione
5.1.5 Other Drug Classes
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Portola Pharmaceuticals Inc.
6.1.2 Boehringer Ingelheim GmbH
6.1.3 CSL Behring Limited
6.1.4 Pfizer Inc.
6.1.5 Octapharma AG
6.1.6 Bausch Health Companies Inc.
6.1.7 Amneal Pharmaceuticals Inc.
6.1.8 Fresenius Kabi AG
6.1.9 Perosphere Pharmaceuticals Inc.
6.1.10 Ferring Pharmaceuticals Inc.
6.1.11 Midas Pharma GmbH
6.1.12 Healthy Life Pharma Pvt. Ltd
6.1.13 Pharma Cure Laboratories
6.1.14 Nischi Lifesciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS